Granted Patent
B2
US 8,541,553 · App. 12/601,780 · Granted Sep 24, 2013
Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
Claims (2)
1. An antibody characterized in that it is produced by the hybridoma cell line having DSMZ accession number DSM ACC2879.
2. A hybridoma cell line having DSMZ accession number DSM ACC2879.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 18, 2013
From: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
To: BAXTER HEALTHCARE SA
Reel/Frame 030034/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 3, 2011
From: HUMER, JOHANNES; MAYER, BERND; MUSTER, THOMAS; WALTENBERGER, ANDREA
To: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
Reel/Frame 025741/0412 →